Mobile

This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) for the treatment of HIV-1 infection The purpose of this study is to test the effectivene...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004011-20

This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) for the treatment of HIV-1 infection The purpose of this study is to test the effectiveness of switching to GS-9883/F/TAF versus continuing on a regimen containing boosted atazanavir (ATV) or darunavir (DRV) plus either emtricitabine/tenofovir (FTC/TDF) or abacavir/lamivudine (ABC/3TC) in virologically suppressed HIV-1 infected adult subjects (HIV-1 RNA < 50 copies/mL)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of switching to a FDC of GS-9883/F/TAF versus continuing on a regimen consisting of boosted atazanavir or darunavir plus either FTC/TDF or ABC/3TC in HIV-1 infected adult subjects who are virologically suppressed as determined by the proportion of subjects with virologic failure (HIV-1 RNA ≥ 50 copies/mL) at Week 48

Critère d'inclusion

  • Human Immunodeficiency Virus (HIV-1) Infection

Liens